Method of treating gastroesophageal reflux disease and nocturnal acid breakthrough

摘要

A method of concurrent treatment for gastroesophageal reflux disease and nocturnal acid breakthrough is described, which comprises the delivery of an GABA_B receptor agonist such as 4-amino-3-(4-chlorophenyl)butanoic acid, in the evening, in a gastric retained drug delivery system.